OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
30 Avril 2024 - 1:00PM
OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage
biopharmaceutical company developing innovative ocular therapies
for the treatment of inflammatory dry eye disease (DED), a
multi-billion-dollar market, and anterior ocular segment diseases
including neuropathic corneal pain (NCP), an ocular condition
associated with pain but without an FDA approved therapy, today
announced an upcoming presentation of the OK-101 Phase 2 data for
dry eye disease at the Dry Horizons Symposium, a partner meeting of
the Association for Research in Vision and Ophthalmology (ARVO),
being held May 3, 2024 in Seattle, WA.
Date: Friday, May 3, 2024,
2:50-3:45 PM PDTVenue: Four Seasons Seattle,
WAPresenter: Gary Jacob, PhD, Chief Executive
Officer
About Dry Horizons
Symposium
Uniting clinical leaders and industry innovators to tackle
significant challenges in the dry eye market. With the rising
prevalence of dry eye disease, the shortcomings of existing
treatments, as well as new opportunities for advancing clinical
pathways based on recent successful therapies, this symposium will
provide in-depth coverage of the global landscape of Dry Eye and
the opportunity for further innovation. From the impact of
technology use on eye health, to unexplored therapeutics, to
accelerating research and development, this new event will showcase
the urgent need for innovative clinical solutions to benefit
current and future patients.
About OKYO
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage
biopharmaceutical company developing innovative therapies for the
treatment of DED and NCP, with ordinary shares listed for trading
on the NASDAQ Capital Market. OKYO is focused on the discovery and
development of novel molecules to treat inflammatory DED and ocular
pain. In addition to the recently completed Phase 2 DED trial, OKYO
also has plans underway for the opening of a Phase 2 trial for
OK-101 to treat NCP in patients with this debilitating condition.
For further information, please visit www.okyopharma.com.
Enquiries:
|
OKYO Pharma Limited |
Gary S. Jacob, Chief Executive Officer |
917-497-7560 |
| Business Development
& Investor Relations |
Paul
Spencer |
+44 (0)20 7495
2379 |
OKYO Pharma (NASDAQ:OKYO)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
OKYO Pharma (NASDAQ:OKYO)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024
